CLDI Profile
Calidi Biotherapeutics, Inc., based in San Diego, California, is a clinical-stage immuno-oncology company focused on developing innovative therapies for cancer treatment. Founded in 2014, Calidi is at the forefront of leveraging cell-based delivery systems to enhance the efficacy and safety of oncolytic virus therapies. The company's approach centers on utilizing potent allogeneic stem cells as vehicles to deliver targeted anti-tumor payloads, aiming to address various oncology indications, including high-grade gliomas and advanced solid tumors.
Calidi's proprietary technology involves advanced cell-based platforms designed to protect, amplify, and potentiate oncolytic viruses. This approach is intended to enhance therapeutic efficacy while minimizing potential side effects. The company's lead product candidates include NeuroNova, which comprises allogeneic neural stem cells loaded with an oncolytic adenovirus. NeuroNova is currently being evaluated for its potential in treating high-grade gliomas, a challenging form of brain cancer.
Additionally, Calidi is developing SuperNova, which features allogeneic adipose-derived mesenchymal stem cells loaded with a tumor-selective CAL1 oncolytic vaccinia virus. This candidate is aimed at treating advanced metastatic solid tumors, leveraging the virus's ability to selectively target and destroy cancer cells. Both product candidates are part of Calidi's broader strategy to advance cell-based oncolytic virus therapies and improve patient outcomes in oncology.
Through its innovative approach and clinical programs, Calidi Biotherapeutics seeks to revolutionize cancer treatment by combining stem cell technology with oncolytic virotherapy. The company's commitment to developing next-generation immunotherapies underscores its role in advancing the field of cancer treatment and addressing unmet medical needs for patients with challenging malignancies.
|
